GondolaBio and Children’s Tumor Foundation Announce Partnership to Advance GondolaBio’s Neurofibromatosis Type 1 Program

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--GondolaBio, a clinical-stage biopharmaceutical company developing novel medicines for patients living with genetic diseases, and the Children’s Tumor Foundation (CTF), NF’s global drug discovery engine focused on neurofibromatosis and schwannomatosis (collectively known as NF), today announced a partnership to advance GondolaBio’s preclinical neurofibromatosis type 1 (NF1) program. CTF will provide guidance as GondolaBio’s NF1 program advances thro